Michele McTigue
Pfizer (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer-related gene regulation, Angiogenesis and VEGF in Cancer, HER2/EGFR in Cancer Research, Cancer therapeutics and mechanisms
Most-Cited Works
- → Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)(2011)909 cited
- → Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema(2000)651 cited
- → Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3(2008)623 cited
- → Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations(2014)574 cited
- → Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors(2012)548 cited
- → Resensitization to Crizotinib by the LorlatinibALKResistance Mutation L1198F(2015)483 cited
- → Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1(2013)410 cited
- → KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients(2009)382 cited
- → Crystal Structures of a Schistosomal Drug and Vaccine Target: Glutathione S-Transferase fromSchistosoma japonicaand its Complex with the Leading Antischistomal Drug Praziquantel(1995)302 cited
- → PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations(2015)268 cited